1h Free Analyst Time
The nuclear medicine market is forecasted to grow by USD 13.01 billion during 2024-2029, accelerating at a CAGR of 19.2% during the forecast period. The report on the nuclear medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing adoption of SPECT/CT hybrid imaging systems, rising utilization of nuclear medicine for early disease detection, and growing cancer cases and rising investment in oncology market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The nuclear medicine market is segmented as below:
By Product
- Radiotherapeutics
- Equipment (SPECT and PET)
By Application
- Oncology
- Cardiology
- Neurology
- Others
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
The report on the nuclear medicine market covers the following areas:
- Nuclear Medicine Market sizing
- Nuclear Medicine Market forecast
- Nuclear Medicine Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Product
9 Market Segmentation by Application
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global nuclear medicine market: Bayer AG, Bracco Spa, Cardinal Health Inc., Eckert and Ziegler AG, ECZACIBASI MONROL NUCLEAR PRODUCTS CO., GE Healthcare Technologies Inc., IBA Radiopharma Solutions, Jubilant Pharmova Ltd., Koninklijke Philips NV, Lantheus, Mallinckrodt Plc, Medi-Radiopharma, Mirion Technologies Inc., Necsa, Novartis AG, Siemens Healthineers AG, Sirtex Medical Pty Ltd., Telix Pharmaceuticals Ltd., Tema Sinergie SpA, and TTG Imaging Solutions LLC.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is minimal side effects of radiopharmaceuticals as compared with its potential benefits."
According to the report, one of the major drivers for this market is the growing adoption of spect/ct hybrid imaging systems.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Bracco Spa
- Cardinal Health Inc.
- Eckert and Ziegler AG
- ECZACIBASI MONROL NUCLEAR PRODUCTS CO.
- GE Healthcare Technologies Inc.
- IBA Radiopharma Solutions
- Jubilant Pharmova Ltd.
- Koninklijke Philips NV
- Lantheus
- Mallinckrodt Plc
- Medi-Radiopharma
- Mirion Technologies Inc.
- Necsa
- Novartis AG
- Siemens Healthineers AG
- Sirtex Medical Pty Ltd.
- Telix Pharmaceuticals Ltd.
- Tema Sinergie SpA
- TTG Imaging Solutions LLC
